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NK cells, which contribute to tumor immunosurveillance, are present in the microenvironment of Non-Small-Cell Lung
Carcinoma. However, they display strongly altered phenotype with decreased expression of NKp30, NKp80, DNAM-1,
CD16 and ILT2, and impaired cytotoxic functions. The possible mechanisms leading to these defects are discussed.
Introduction
Natural killer (NK) cells are innate immune
effector cells capable of recognizing and
killing tumor cells through the release of
cytotoxic enzymes and cytokines. The
importance of NK cell-mediated tumor
immunosurveillance has been underlined
in NK cell-deficient mouse models but
limited informations are available in
humans. Several studies conducted on
intratumoral NK cells from human solid
tumors indicate that their phenotype and
function are largely altered.
1-4
In NSCLC, distinct immune cells
infiltrate both the tumor nest and the
stroma. Among these cells, the density of
mature dendritic cells and CD3
+ T cells
in Tumor induced-Bronchus-Associated
Lymphoid Tissue is associated with a
favorable clinical outcome.
5 Our recent
study performed on 86 early stages
NSCLC patients revealed that NKp46
+
cells infiltrate the tumor environment.
6
NK Cells are Modulated by the
NSCLC Microenvironment
We conducted a series of prospective
studies to determine the phenotype of
intratumoral NK cells, and compared it
with the peripheral blood, normal lung,
emphysema or bronchectasis tissue.
Among the 17 NK receptors studied, the
expression of NKp30, NKp80, DNAM-1,
CD16 and ILT2 was specifically decreased
on intratumoral NK cells and the expres-
sion of CD69 and NKp44 activation
markers was increased. Unsupervised hier-
archical clustering of cell surface marker
expression revealed two groups of patients,
with one group in which the expression of
the five receptors was highly downregu-
lated. We did not yet get the clinical
follow up of the patients, but we can
speculate that the impact on NK cells on
clinical outcome of the patients, if any,
should be more dependent on NK cell
phenotype than on the NK cell density
in the tumor microenvironment. With
respect to this hypothesis, we did not find
that the density of NK cells either in the
invasive margin or in the stroma of the
tumor was associated with good or bad
clinical outcome of patients.
6
According to this altered phenotype,
NK cells functions were also found altered,
with impaired degranulation capacities
and IFNc secretion, which could not be
reversed following in vitro stimulation
with IL-2. These impaired functions are
likely due to a lack of stimulation of NK
cells by tumor cells through activating
NK receptors that were found decreased.
Moreover, the decrease of CD16 expres-
sion should also impair the capacity of NK
cells to mediate cell killing by ADCC.
Coculture experiments of NK cells from
blood of healthy donors with NSCLC cell
lines induced a downregulation of the
same activating receptors, indicating that
membrane or soluble factors expressed by
tumor cells affect the NK cell phenotype.
Among these factors, we identified TGF 
as a downregulation factor for NKp30 and
NKp80.
6
Thus, our study suggests that pheno-
type and cytotoxic functions of NK cells
is largely suppressed in the tumor micro-
environment by a number of distinct
effectors and secreted factors.
Possible Causes of NK Cells
Modulation in the Tumor
Microenvironment
Increasing numbers of human studies
reveal that the phenotype and the func-
tions of NK cells are altered in the tumor
microenvironment. We speculate that
these alterations can be related to several
mechanisms, including downregulation of
receptor expression, shedding of the recep-
tors (Fig.1), or induction of a particular
differentiation program of NK cells.
First, the modification of the phenotype
and the function of NK cells can be altered
in the immunosuppressive tumor micro-
environment due to the high expression
of membrane or soluble factors such as
TGF , PGE2 (prostaglandin E2), LGALS3
(Galectin 3) or IDO.
3 In NSCLC, we
observed a downregulation of NKp30,
NKp80, ILT2 and DNAM1 on NK
cells after a coculture with lung tumor
cells, and showed that this downregulation
was dependent to cell-to-cell contact
and/or TGF . Soluble ligands for activating
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receptors may also downregulate NK recep-
tors as it has been observed for sMICA/B
and NKG2D. Second, the NK cells can be
exhausted after tumor cells recognition and
activation. It has been demonstrated that a
prolonged contact of NK and tumor cells
can result in the downregulation of NK
receptors, such as DNAM-1, and decreased
cytotoxic activity.
2 In some patients the
tumor cells express the NKG2D, DNAM-
1,aswell asNCR ligandswhichcan interact
with their cognate receptors expressed by
intratumoral NK cells.
6 Finally, we also
speculate that NK cells after being recruited
in the tumor site, sustain a particular
developmental program of differentiation.
The comparison of the gene expression
profiles of NK subpopulations from the
peripheral blood and from the tumor may
help to decipher mechanisms leading to this
particular phenotype.
Intratumoral NK Cells:
Good or Bad for the Patient ?
In contrast to components of the adaptive
immune response such as mature DC, or
Th1 and CD8 T cells,
5,7 and in accordance
with their intratumoral NK cell pheno-
type, we did not find a correlation between
the density of NK cells either in the
invasive margin or in the stroma of tumors
and the clinical outcome of patients.
6
Immunohistochemistry analysis of our
cohort of patients revealed that NK cells
are also present in non tumoral lung
tissues, where they have a phenotype
similar to NK cells from peripheral blood.
It is therefore tempting to speculate that
NK cells might have been present and
have antitumoral cytotoxic activity at very
early stages of tumor development and
that their phenotype was progressively
altered during tumor progression.
It cannot be excluded that intratumoral
NK cells may have deleterious effects on
other immune cells located in the tumor
microenvironment. For instance they
might cause inefficient DC maturation
because of the lack of IFN-c secretion
by NK cells. A concomitant analysis
of immature DC and NK cells in situ
would help to reinforce this hypothesis,
since we have already observed the
presence of immature DC in the stroma
of NSCLC.
8 NK cells could also favor the
recruitment of regulatory T cells, that have
been described in the tumor environ-
ment,
9 through CCL22 chemokine secre-
tion, as it has been observed in a murine
model.
10
Concluding Remarks
A question of high importance is now to
determine if the modifications of intra-
tumoral NK phenotype and functions are
reversible. If that is the case, enhancing
NK cell function with immunostimulatory
cytokines, such as IL-15, IL-18 and type I
IFN or by neutralization of immuno-
suppressive factors produced in the
environment might further ameliorate the
clinical outcome of NSCLC.
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Figure1. Possible mechanisms leading to intratumoral NK cell alterations: NK cells infiltrating lung
carcinoma display altered expression of NKp30, NKp80, DNAM-1 and CD16 and impaired capacities
of CD107 expression and IFNc secretion. Tumor cells produce soluble molecules such as IDO, PGE2,
TGBb and/or express membrane molecules (NK ligands) that can downregulate or shed receptors at
the surface of NK cells. NK cells can also be inhibited by TGFb produced by regulatory T cells, that
are present in the NSCLC tumor microenvironment. In addition, intratumoral NK display impaired
IFNc secretion that can cause inefficient DC maturation.
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